AFMDのチャート
AFMDの企業情報
| symbol | AFMD |
|---|---|
| 会社名 | Affimed N.V. （アフィメド） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13 AFM11 AFM21 AFM22 AFM24 TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22 which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia. アフィメドはドイツのバイオ医薬品会社の持株会社。同社は2000年設立。ハイデルベルクのドイツがん研究センタ―で開発された技術をもとに、腫瘍細胞への自己免疫力を高める革新的なアプロ―チによるがん治療法の研究、開発、商品化に従事。開発中の製品にAFM13、AFM11、AFM21を含む。 Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives. |
| 本社所在地 | Technologiepark Im Neuenheimer Feld 582 Heidelberg 69120 DEU |
| 代表者氏名 | Thomas Hecht トーマス・ヘクト |
| 代表者役職名 | Chairman of the Supervisory Board |
| 電話番号 | +49 6221-67-4360 |
| 設立年月日 | 41760 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.affimed.com |
| nasdaq_url | https://www.nasdaq.com/symbol/afmd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -34.24747 |
| 終値（lastsale） | 4.62 |
| 時価総額（marketcap） | 288242114.16 |
| 時価総額 | 時価総額（百万ドル） 218.36520 |
| 売上高 | 売上高（百万ドル） 2.05078 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 170.73193 |
| 当期純利益 | 当期純利益（百万ドル） -35.31480 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Affimed NV revenues decreased 25% to EUR682K. Net loss increased 3% to EUR16.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses - Bala increase of 23% to EUR13.1M (expense) Interest Expense Net increase from EUR168K to EUR466K (expense). |
AFMDのテクニカル分析
AFMDのニュース
Affimed N.V. (AFMD) can beat the pack with these strategies 2023/02/23 16:24:00 US Post News
In Wednesday’s session, Affimed N.V. (NASDAQ:AFMD) marked $0.97 per share, down from $0.99 in the previous session. While Affimed N.V. has underperformed by -2.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -77.09%, with highs and lows ranging from $5.10 to $0.98, whereas […]
Alluring stocks: Affimed N.V. (NASDAQ:AFMD -2.22%), Ambrx Biopharma Inc. (NYSE:AMAM 0.22%) 2023/02/23 13:50:18 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Alluring stocks: Affimed N.V. (NASDAQ:AFMD -2.22%), Ambrx Biopharma Inc. (NYSE:AMAM 0.22%) appeared first on Stocks Equity .
Current Investor’s Watch List: Bit Digital, Inc. (NASDAQ:BTBT), Affimed N.V. (NASDAQ:AFMD) 2023/02/22 18:18:24 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Current Investor’s Watch List: Bit Digital, Inc. (NASDAQ:BTBT), Affimed N.V. (NASDAQ:AFMD) appeared first on Stocks Equity .
Spellbinding stocks: Affimed N.V. (NASDAQ:AFMD -3.04%), Avino Silver & Gold Mines Ltd. (AMEX:ASM -3.42%) 2023/02/22 07:47:11 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Spellbinding stocks: Affimed N.V. (NASDAQ:AFMD -3.04%), Avino Silver & Gold Mines Ltd. (AMEX:ASM -3.42%) appeared first on Stocks Equity .
Is Affimed N.V. (NASDAQ: AFMD) Stock Set To Rise More? 2023/02/21 19:00:00 Marketing Sentinel
In the latest trading session, 0.56 million Affimed N.V. (NASDAQ:AFMD) shares changed hands as the company’s beta touched 2.53. With the company’s most recent per share price at $1.00 changed hands at -$0.02 or -1.47% at last look, the market valuation stands at $145.90M. AFMD’s current price is a discount, trading about -410.0% off its … Is Affimed N.V. (NASDAQ: AFMD) Stock Set To Rise More? Read More »
Affimed N.V. (NASDAQ: AFMD) Stock: Does It Have The Potential To Rise? 2022/11/16 16:30:00 Marketing Sentinel
In the last trading session, 2.71 million shares of the Affimed N.V. (NASDAQ:AFMD) were traded, and its beta was 2.20. Most recently the company’s share price was $2.27, and it changed around $0.23 or 11.27% from the last close, which brings the market valuation of the company to $348.04M. AFMD currently trades at a discount … Affimed N.V. (NASDAQ: AFMD) Stock: Does It Have The Potential To Rise? Read More »
Affimed N.V. (AFMD) Q3 2022 Earnings Call Transcript 2022/11/15 23:44:03 Seeking Alpha
Affimed N.V. (NASDAQ:NASDAQ:AFMD) Q3 2022 Earnings Conference Call November 15, 2022, 08:30 AM ET Company Participants Alex Fudukidis - Director of IR Adi Hoess - CEO Andreas Harstrick -…
A stock that deserves closer examination: Affimed N.V. (AFMD) 2022/11/15 16:24:00 US Post News
A share of Affimed N.V. (NASDAQ:AFMD) closed at $2.04 per share on Monday, down from $2.17 day before. While Affimed N.V. has underperformed by -5.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -65.48%, with highs and lows ranging from $7.35 to $1.40, […]
Affimed NV Earnings, Revenue Beat in Q3 By Investing.com 2022/11/15 11:44:00 Investing.com
Affimed NV Earnings, Revenue Beat in Q3
Earnings Scheduled For November 15, 2022 2022/11/15 09:07:59 Benzinga
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ: WTER ) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million. • Home Depot (NYSE: HD ) is likely to report quarterly earnings at $4.13 per share on revenue of $38.01 billion. • AgEagle Aerial Sys (AMEX: UAVS ) is expected to report earnings for its third quarter. • Data Storage (NASDAQ: DTST ) is expected to report quarterly loss at $0.06 per share on revenue of $5.50 million. • BioLine Rx (NASDAQ: BLRX ) is expected to report earnings for its third quarter. • Milestone Scientific (AMEX: MLSS ) is likely to report quarterly loss at $0.03 per share on revenue of $2.09 million. • Quhuo (NASDAQ: QH ) is expected to report quarterly loss at $0.44 per share on revenue of $136.15 million. • Affimed (NASDAQ: AFMD ) is projected to report quarterly loss at $0.18 per share on revenue of $7.59 million. • China Index Holdings (NASDAQ: CIH ) is projected to report earnings for its third quarter. • Moving iMage Technologies (AMEX: MITQ ) is expected to report earnings for its first quarter. • Evoqua Water Technologies (NYSE: AQUA ) is expected to report quarterly earnings at $0.32 per share on revenue of $465.73 million. • GreenPower Motor Co (NASDAQ: GP ) is likely to report quarterly loss at $0.16 per share on revenue of $6.69 million. • Reliance Global Group (NASDAQ: RELI ) is estimated to report quarterly loss at $0.07 per share on revenue of $5.60 million. • BM Technologies (AMEX: BMTX ) is likely to report quarterly earnings at $0.30 per share on revenue of $23.94 million. • Exscientia (NASDAQ: EXAI ) is estimated to report quarterly loss at $0.32 per share on revenue of $15.91 million. • Blackboxstocks (NASDAQ: BLBX ) is projected to report quarterly loss at $0.07 per share on revenue of $1.30 million. • iSun (NASDAQ: ISUN ) is likely to report earnings for its third quarter. • Eagle Point Credit …
Affimed N.V. (NASDAQ:AFMD) Jumps 0.50%, But Further Rally Could Be Imminent 2022/09/23 13:00:00 Marketing Sentinel
In last trading session, Affimed N.V. (NASDAQ:AFMD) saw 1.1 million shares changing hands with its beta currently measuring 2.30. Company’s recent per share price level of $2.03 trading at $0.01 or 0.50% at ring of the bell on the day assigns it a market valuation of $333.45M. That closing price of AFMD’s stock is at … Affimed N.V. (NASDAQ:AFMD) Jumps 0.50%, But Further Rally Could Be Imminent Read More »
How should investors view Affimed N.V. (AFMD)? 2022/09/20 15:48:00 US Post News
In Monday’s session, Affimed N.V. (NASDAQ:AFMD) marked $2.16 per share, down from $2.23 in the previous session. While Affimed N.V. has underperformed by -3.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -66.20%, with highs and lows ranging from $7.35 to $2.17, whereas […]
Affimed N.V. (AFMD) can beat the pack with these strategies 2022/09/14 11:00:00 US Post News
As of Tuesday, Affimed N.V.’s (NASDAQ:AFMD) stock closed at $2.64, down from $2.76 the previous day. While Affimed N.V. has underperformed by -4.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -58.56%, with highs and lows ranging from $7.35 to $2.23, whereas the […]
Affimed N.V. (NASDAQ: AFMD) Stock Forecast: Bearish Views Expect -247.84 Percent Drop In 2022 2022/09/13 17:00:00 Stocks Register
The trading price of Affimed N.V. (NASDAQ:AFMD) floating higher at last check on Tuesday, September 13, closing at $2.78, 0.54% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $2.67 and $2.795. In examining the 52-week price action we see that the … Affimed N.V. (NASDAQ: AFMD) Stock Forecast: Bearish Views Expect -247.84 Percent Drop In 2022 Read More »
Affimed N.V. (NASDAQ: AFMD) Stock Could Be An Option To Consider 2022/08/25 15:00:00 Stocks Register
Affimed N.V. (NASDAQ:AFMD) shares, rose in value on Wednesday, 08/24/22, with the stock price up by 1.06% to the previous day’s close as strong demand from buyers drove the stock to $2.85. Actively observing the price movement in the last trading, the stock closed the session at $2.82, falling within a range of $2.78 and … Affimed N.V. (NASDAQ: AFMD) Stock Could Be An Option To Consider Read More »